The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can help to align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment plans for the treatment and management of nuclear paralysis PSP require individualized development, usually including multidimensional management of drug therapy, rehabilitation, regular follow-up, and so on. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many neurological diseases that have been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of PPSP. The platform serves a team of nationally and internationally authoritative experts in the field of neural systems related to the Chinese international medical service system, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.